Stock listing
NASDAQ:SNTI Senti Biosciences Holdings, Inc. Stock
Home listing (NASDAQ) of Senti Biosciences Holdings, Inc.
Follow Senti Biosciences Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SNTI
$1.77 USD -1.02 (-36.6%)
Close on Nov 20, 2026
- Day range
- $1.71 – $2.59 USDNov 20, 2026
- Volume
- 39,024 sharesNov 20, 2026
- Market cap
- $2.06M USDAt the close on Nov 20, 2026 · price × 1.17M shares outstanding
- 52-week range
- $1.71 – $95.04 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $24,965 USDMedian day 252 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SNTI · Home | $1.77 USD | -1.02 (-36.6%) | 39,024 | $2.58 | $2.59 | $1.71 | $2.79 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SNTI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.77 | -1.02 | -36.6% | $2.58 | $2.59 | $1.71 | 39,024 | |
| $2.79 | -0.081 | -2.8% | $2.85 | $3.015 | $2.50 | 50,083 | |
| $2.871 | -0.33 | -10.3% | $3.102 | $3.201 | $2.805 | 437 | |
| $3.201 | -1.287 | -28.7% | $3.666 | $3.808 | $2.97 | 563 | |
| $4.488 | -0.132 | -2.9% | $4.607 | $5.013 | $4.389 | 502 | |
| $4.62 | -0.231 | -4.8% | $4.851 | $5.148 | $4.62 | 77 | |
| $4.851 | -0.33 | -6.4% | $5.082 | $5.247 | $4.818 | 139 | |
| $5.181 | +0.528 | +11.3% | $4.587 | $5.247 | $4.587 | 205 | |
| $4.653 | -0.594 | -11.3% | $5.181 | $5.445 | $4.554 | 316 | |
| $5.247 | -0.033 | -0.6% | $5.28 | $5.412 | $5.082 | 213 | |
| $5.28 | -0.165 | -3.0% | $5.115 | $5.478 | $5.115 | 160 | |
| $5.445 | -0.396 | -6.8% | $5.709 | $5.709 | $5.082 | 263 | |
| $5.841 | -0.033 | -0.6% | $6.006 | $6.006 | $5.28 | 382 | |
| $5.874 | -0.33 | -5.3% | $6.072 | $6.171 | $5.709 | 241 | |
| $6.204 | +0.759 | +13.9% | $5.676 | $6.732 | $5.148 | 820 | |
| $5.445 | -1.716 | -24.0% | $5.709 | $6.60 | $5.016 | 1,470 | |
| $7.161 | +0.066 | +0.9% | $7.062 | $7.854 | $6.831 | 1,677 | |
| $7.095 | +0.924 | +15.0% | $5.973 | $7.623 | $5.973 | 9,176 | |
| $6.171 | +0.396 | +6.9% | $5.544 | $6.435 | $5.148 | 80,320 | |
| $5.775 | -0.429 | -6.9% | $6.138 | $6.138 | $5.643 | 65,119 | |
| $6.204 | -0.099 | -1.6% | $6.105 | $6.237 | $5.61 | 336 | |
| $6.303 | -0.891 | -12.4% | $6.93 | $7.062 | $6.138 | 183 | |
| $7.194 | -0.33 | -4.4% | $7.293 | $7.293 | $6.93 | 230 | |
| $7.524 | +0.033 | +0.4% | $7.062 | $7.59 | $6.963 | 267 | |
| $7.491 | +0.066 | +0.9% | $7.194 | $7.722 | $7.062 | 276 | |
| $7.425 | -1.221 | -14.1% | $8.184 | $8.349 | $6.996 | 3,214 | |
| $8.646 | +0.693 | +8.7% | $7.92 | $8.646 | $7.92 | 17,437 | |
| $7.953 | -0.462 | -5.5% | $8.349 | $8.646 | $7.92 | 153 | |
| $8.415 | -2.112 | -20.1% | $10.23 | $10.26 | $8.316 | 278 | |
| $10.53 | +0.165 | +1.6% | $10.26 | $10.63 | $10.23 | 131 | |
| $10.36 | -0.264 | -2.5% | $10.69 | $10.69 | $10.23 | 101 | |
| $10.63 | -0.264 | -2.4% | $10.33 | $10.86 | $10.33 | 227 | |
| $10.89 | +0.231 | +2.2% | $10.33 | $11.55 | $10.33 | 304 | |
| $10.66 | -0.726 | -6.4% | $10.73 | $11.22 | $10.30 | 187 | |
| $11.38 | +0.759 | +7.1% | $10.23 | $11.38 | $10.23 | 347 | |
| $10.63 | -0.066 | -0.6% | $10.40 | $10.76 | $10.23 | 114 | |
| $10.69 | +0.396 | +3.8% | $10.40 | $11.06 | $9.90 | 563 | |
| $10.30 | +0.132 | +1.3% | $10.03 | $10.43 | $10.03 | 77 | |
| $10.16 | -0.066 | -0.6% | $10.26 | $11.12 | $9.933 | 268 | |
| $10.23 | -0.627 | -5.8% | $10.89 | $11.22 | $10.23 | 504 | |
| $10.86 | -0.462 | -4.1% | $10.56 | $11.12 | $10.07 | 845 | |
| $11.32 | +0.165 | +1.5% | $11.55 | $12.21 | $10.92 | 2,116 | |
| $11.15 | +0.726 | +7.0% | $10.89 | $11.88 | $10.63 | 9,521 | |
| $10.43 | +0.198 | +1.9% | $10.33 | $11.35 | $10.26 | 169 | |
| $10.23 | -0.33 | -3.1% | $10.56 | $10.69 | $10.23 | 95 | |
| $10.56 | +0.231 | +2.2% | $10.56 | $10.82 | $10.07 | 195 | |
| $10.33 | +0.066 | +0.6% | $10.49 | $10.86 | $9.933 | 285 | |
| $10.26 | +0.363 | +3.7% | $10.13 | $10.96 | $9.57 | 5,771 | |
| $9.90 | -0.066 | -0.7% | $9.90 | $10.59 | $9.603 | 198 | |
| $9.966 | -0.132 | -1.3% | $10.23 | $10.23 | $9.966 | 28 | |
| $10.10 | +0.198 | +2.0% | $9.90 | $10.56 | $9.90 | 103 | |
| $9.90 | +0.033 | +0.3% | $10.43 | $10.43 | $9.669 | 107 | |
| $9.867 | -0.561 | -5.4% | $10.66 | $10.66 | $9.57 | 136 | |
| $10.43 | -0.561 | -5.1% | $10.99 | $11.22 | $10.23 | 400 | |
| $10.99 | -0.264 | -2.3% | $11.55 | $11.88 | $10.92 | 122 | |
| $11.25 | -0.033 | -0.3% | $12.18 | $12.47 | $11.25 | 39 | |
| $11.29 | +0.066 | +0.6% | $11.25 | $11.95 | $11.25 | 36 | |
| $11.22 | -1.254 | -10.1% | $12.54 | $12.54 | $11.22 | 66 | |
| $12.47 | +0.033 | +0.3% | $12.01 | $12.67 | $11.88 | 22 | |
| $12.44 | -0.033 | -0.3% | $12.90 | $13.13 | $12.05 | 83 | |
| $12.47 | -0.264 | -2.1% | $12.77 | $13.13 | $11.65 | 131 | |
| $12.74 | -0.165 | -1.3% | $12.94 | $13.20 | $12.21 | 68 | |
| $12.90 | +0.429 | +3.4% | $12.54 | $13.27 | $12.18 | 164 | |
| $12.47 | -0.363 | -2.8% | $12.54 | $12.84 | $10.92 | 694 | |
| $12.84 | -1.551 | -10.8% | $14.39 | $14.52 | $11.88 | 696 | |
| $14.39 | -0.891 | -5.8% | $15.28 | $15.48 | $14.39 | 92 |
Splits
2 splits since 2024 · NASDAQ:SNTI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-33 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:SNTI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Senti Bio Announces Reverse Stock Split
Latest deck · Dec 9, 2025
Corporate Update (December 2025)
Corporate update · 34 slides
Latest news
Senti Bio Announces Reverse Stock Split
Nov 17, 2026
Closed $3.20 (-28.7%) on Nov 17, 2026
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
Jul 15, 2026
Closed $19.24 (-39.8%) on Jul 15, 2026
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
May 14, 2026
Closed $34.32 (+8.0%) on May 14, 2026
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
Apr 13, 2026
Closed $29.73 (+3.2%) on Apr 13, 2026
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
Apr 1, 2026
Closed $27.69 (+3.3%) on Apr 1, 2026
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Mar 27, 2026
Closed $26.07 (-10.3%) on Mar 27, 2026
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
Mar 23, 2026
Closed $29.70 (-2.2%) on Mar 23, 2026
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Mar 3, 2026
Closed $31.38 (+2.1%) on Mar 3, 2026
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Feb 24, 2026
Closed $30.69 (+7.0%) on Feb 24, 2026
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Feb 20, 2026
Closed $28.38 (-3.4%) on Feb 20, 2026
Senti Biosciences Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 85 in all · newest Nov 17, 2026 · oldest 2021
- Decks
- 10 decks · latest Dec 9, 2025
Where Senti Biosciences Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SNTI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SNTI | BOATS | United States | USD |
Valuation
EV/sales −47.2× against a median of 1.5×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.49M USD
- P/E
- Loss
- EV/sales
- −47.2×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 2.91
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Senti Biosciences Holdings, Inc. · NASDAQ:SNTI | US$2.06M | −US$3.49M | n/a | −47.2× | n/a | n/a | n/a | n/a | 2.91 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Modus Therapeutics Holding AB · OMXSTO:MODTX | US$2.22M | US$1.00M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Nuformix PLC · LSE:NFX | US$2.22M | US$1.00M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Medicus Pharma Ltd. · NASDAQ:MDCX | US$2.18M | −US$2.73M | n/a | n/a | n/a | n/a | n/a | n/a | 2.03 |
| CASI Pharmaceuticals, Inc. · OTC:CASIF | US$2.06M | US$38.79M | n/a | 1.9× | n/a | n/a | −218.6% | n/a | -0.07 |
| Vectus Biosystems Limited · ASX:VBS | US$2.02M | US$50,946 | 1.9× | n/a | n/a | 1.3× | n/a | 0.2× | n/a |
| Decoy Therapeutics Inc. · NASDAQ:DCOY | US$1.98M | −US$6.19M | n/a | −11.6× | n/a | 0.4× | n/a | 0.0× | 1.28 |
| Genprex, Inc. · NASDAQ:GNPX | US$1.94M | −US$13.41M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.08 |
| Median of the others | US$2.20M | −US$1.34M | 1.9× | 1.5× | 0.5× | −379.5% | 0.0× | 1.18 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 13.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.04 · 2 analysts
- Revenue, year to Dec 2026
- 50K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jenene Thomas | Chief Executive Officer |
| Jay Cross | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Bryan Baum | Director |
| Feng Hsiung | Director |
| Fran Schulz | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −28.7% |
| Q2 2026 | Aug 14, 2026 · After close | −4.2% |
| Q1 2026 | May 14, 2026 · Before open | +8.0% |
| Q4 2025 | Mar 27, 2026 | −12.4% |
| Q3 2025 | Nov 13, 2025 · After close | −10.1% |
| Q2 2025 | Aug 7, 2025 · Before open | −8.9% |
| Q1 2025 | May 6, 2025 · After close | +0.6% |
| Q4 2024 | Mar 20, 2025 | +1.7% |
| Q3 2024 | Nov 15, 2024 | −10.3% |
| Q2 2024 | Aug 9, 2024 · Before open | −4.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −0.3% |
| Q4 2023 | Mar 21, 2024 · After close | −6.6% |
| Q3 2023 | Nov 14, 2023 · Before open | −19.4% |
| Q2 2023 | Aug 11, 2023 · Before open | +0.1% |
| Q1 2023 | May 9, 2023 · After close | −8.0% |
| Q4 2022 | Mar 22, 2023 · After close | +2.5% |
| Q3 2022 | Nov 10, 2022 · After close | −1.6% |
| Q2 2022 | Aug 15, 2022 · After close | −2.0% |
| Q1 2022 | May 16, 2022 · After close | 0.0% |
| Q4 2021 | Mar 7, 2022 | −0.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (December 2025) | Corporate update | 34 slides | Dec 9, 2025 |
| Technical Presentation (April 2025) | Technical | 25 slides | Apr 28, 2025 |
| Technical Presentation (December 2024) | Technical | 21 slides | Dec 3, 2024 |
| Investor Presentation (January 2023) | Investor deck | 39 slides | Jan 27, 2023 |
| Investor Presentation (January 2023) | Investor deck | 35 slides | Jan 9, 2023 |
| Investor Presentation (December 2022) | Investor deck | 34 slides | Dec 12, 2022 |
| Investor Day (December 2022) | Investor day | 34 slides | Dec 12, 2022 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | Nov 10, 2022 |
| Investor Presentation (October 2022) | Investor deck | 30 slides | Oct 3, 2022 |
| SPAC Merger (December 2021) | SPAC merger | 52 slides | Dec 20, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of pIPE financing securities Made bigger: US$47.6M · upon stockholder approval, warrants to purchase up to an additional 25,069,500 shares… · Leerink Partners Dealers: Leerink Partners (lead) Buyers: Celadon Partners (additional investment of approximately $10.0 million; led the PIPE financing); New Enterprise Associates (NEA); Leaps by Bayer; Nantahala Capital; The Red Hook Fund LP Use of proceeds: Fund continued development of SENTI-202 program and manufacturing ramp-up, other R&D, and general corporate purposes | Jan 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Dynamics Special Purpose Corp., a blank check company (SPAC). Priced at US$10.00 a share on May 25, 2021.
- Price
- US$10.00 a share
- Shares offered
- 20,000,000 shares of Class A common stock
- Offering size
- US$200 million
- Underwriters' option
- Up to 3,000,000 more shares
- Underwriter
- J.P. Morgan
- Shares delivered
- On or about May 28, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 2, 2021 |
| Filed publicly | May 7, 2021 |
| Amended twice | Newest May 24, 2021 |
| Shares registered with an exchange | May 25, 2021 |
| Declared effective by the SEC | May 25, 2021 |
| Final prospectus, with the price | May 27, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B5 · Prospectus | May 27, 2021 |
| EFFECT · Notice that a registration is effective | May 25, 2021 |
| CERT · Exchange's certificate of listing | May 25, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | May 25, 2021 |
| CORRESP · Letter to the SEC | May 24, 2021 |
| CORRESP · Letter to the SEC | May 24, 2021 |
| S-1/A · Registration statement, amended | May 24, 2021 |
| S-1/A · Registration statement, amended | May 21, 2021 |
| CORRESP · Letter to the SEC | May 20, 2021 |
| UPLOAD · Letter from the SEC | May 19, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | May 7, 2021 |
| S-1 · Registration statement | May 7, 2021 |
| UPLOAD · Letter from the SEC | Apr 29, 2021 |
| DRS · Draft registration statement | Apr 2, 2021 |
Open IPO · From the cover of the final prospectus (424B5) filed May 27, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 22.0K | 0 | 2.56M | 4.29M | 2.76M | 394.0K | 85.0K |
| Cost of revenue | 3.64M | 5.24M | 3.92M | 3.01M | 16.0M | 14.5M | |
| Gross profit | -3.62M | 1.98M | 4.29M | 2.29M | 394.0K | -14.4M | |
| Research and development | 37.6M | 34.4M | 32.1M | 28.1M | 22.0M | 16.0M | 14.5M |
| Selling, general and administrative | 26.2M | 23.5M | 34.9M | 40.8M | 21.3M | 9.30M | 7.34M |
| Operating income | -68.8M | -61.0M | -92.7M | -62.1M | -40.4M | -24.7M | -21.8M |
| Depreciation and amortization | 3.64M | 3.84M | 3.56M | 1.40M | 769.0K | 1.99M | 1.40M |
| EBITDA | -65.1M | -57.2M | -89.2M | -60.7M | -39.7M | -22.7M | -20.4M |
| Interest expense | 3.92M | 11.0K | 88.0K | 0 | |||
| Income before tax | -61.4M | -52.8M | -83.4M | -58.2M | -55.3M | -19.9M | -21.2M |
| Income tax | 0 | 0 | 9.51M | -12.4M | 11.0K | 150.0K | |
| Net income | -61.4M | -52.8M | -71.1M | -58.2M | -55.3M | -19.9M | -21.2M |
| Earnings per share, basic | -2.73 | -12.03 | -16.01 | -2.23 | -19.00 | -4.55 | -15.57 |
| Earnings per share, diluted | -2.73 | -12.03 | -16.01 | -2.23 | -19.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.4M | 48.3M | 35.9M | 57.6M | 56.0M | 30.5M | 5.30M |
| Short-term investments | 0 | 40.9M | 0 | 25.0K | 12.5M | ||
| Receivables | 1.59M | 1.80M | 17.7M | 626.0K | 483.0K | 317.0K | 78.0K |
| Inventory | 335.0K | 3.29M | 2.60M | 25.0K | |||
| Current assets | 23.3M | 59.0M | 71.2M | 102.6M | 60.2M | 31.7M | 18.8M |
| Property, plant and equipment | 12.9M | 21.3M | 25.3M | 51.4M | 12.4M | 16.1M | 16.6M |
| Total assets | 51.2M | 97.8M | 119.5M | 180.8M | 96.7M | 48.3M | 35.8M |
| Accounts payable | 2.94M | 1.45M | 1.25M | 1.37M | 5.19M | 914.0K | 1.20M |
| Current liabilities | 14.0M | 13.1M | 12.7M | 18.1M | 14.5M | 4.87M | 4.31M |
| Total debt | 28.9M | 33.6M | 37.7M | 37.1M | 22.7M | 14.0M | |
| Total liabilities | 45.6M | 47.1M | 52.6M | 53.5M | 36.3M | 107.1M | 17.9M |
| Shareholders' equity | 5.59M | 25.6M | 66.9M | 127.3M | -111.5M | -58.7M | 18.0M |
| Shares outstanding | 30.9M | 4.83M | 4.57M | 44.1M | 2.97M | 4.37M | 1.36M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -43.4M | -41.4M | -52.4M | -34.9M | -34.6M | -24.2M | -18.4M |
| Capital spending | -196.0K | -26.0K | -12.0M | -41.4M | -5.54M | -1.16M | -2.00M |
| Free cash flow | -43.6M | -41.4M | -64.4M | -76.3M | -40.2M | -25.3M | -20.4M |
| Cash from investing | -184.0K | 34.0K | 30.1M | -82.0M | -5.54M | 11.4M | 3.75M |
| Cash from financing | 11.8M | 53.7M | 779.0K | 118.6M | 68.4M | 38.1M | 14.0M |
| Dividends paid | -404.0K | -5.17M | -3.89K | ||||
| Share buybacks | 512.0K | 196.0K | |||||
| Change in cash | -31.9M | 12.4M | -21.5M | 1.70M | 28.3M | 25.2M | 5.80M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 20, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 26, 2026 | Acquisition or disposal | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Oct 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 25, 2026 | Other filings | SEC |
| DEFM14A | Sep 24, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Sep 24, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2026 | Management or board change | SEC |
| PRER14A | Sep 23, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 22, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 11, 2026 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Sep 10, 2026 | Offer document | SEC |
| PRER14A | Sep 4, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Sep 4, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 4, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Sep 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 2, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Aug 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 20, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Jul 21, 2026 | Annual report | SEC |
| PREM14A | Jul 21, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 16, 2026 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Jul 16, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Jul 15, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 15, 2026 | Results | SEC |
| S-3 · Registration statement | Jun 18, 2026 | Offer document | SEC |
| D | Jun 3, 2026 | Other filings | SEC |
| 8-K · Current report | May 26, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 15-12G | May 8, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 4, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | May 1, 2026 | Offer document | SEC |
| 8-K · Current report | May 1, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2026 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Apr 24, 2026 | Offer document | SEC |
| S-8 POS | Apr 24, 2026 | Offer document | SEC |
| S-8 POS | Apr 24, 2026 | Offer document | SEC |
| S-8 POS | Apr 24, 2026 | Offer document | SEC |
| S-8 POS | Apr 24, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 24, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 24, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 24, 2026 | Offer document | SEC |
| 8-K12B | Apr 24, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 24, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 31, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 8-K · Current report | Mar 19, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 9, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 2, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 18, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 30, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 26, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 26, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 24, 2025 | Material contract | SEC |
| S-3 · Registration statement | Mar 21, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 21, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 13, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 10, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 7, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 7, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Feb 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2025 | Management or board change | SEC |
| DEF 14A · Proxy statement | Jan 27, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 6, 2025 | Financing | SEC |
| D | Dec 19, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 2, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 2, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Oct 25, 2024 | Current report | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Jul 17, 2024 | Current report | SEC |
| 8-K · Current report | Jul 16, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 12, 2024 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | May 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 17, 2024 | Management or board change | SEC |
| 3 · Initial statement of ownership | May 9, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 8-K · Current report | May 2, 2024 | Management or board change | SEC |
| 10-K/A · Annual report, amended | Apr 26, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 26, 2024 | Management or board change | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 8-K · Current report | Feb 6, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 10, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 5, 2024 | Current report | SEC |
| 8-K · Current report | Dec 22, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 424B3 · Prospectus | Nov 13, 2023 | Offer document | SEC |
| 424B3 · Prospectus | Nov 13, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2023 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Nov 6, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 6, 2023 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Nov 1, 2023 | Offer document | SEC |
This page holds 200 of 375 filings. Open Filings
Cap table
Built by 6ix from Senti Biosciences Holdings, Inc.’s releases · as of Nov 19, 2026
- Common shares
- 1,165,313
- Fully diluted
- 1,165,313
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,165,313 | Nov 19, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 19, 2026 | 1,165,313 |
| Nov 19, 2026 | |
| Nov 17, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward Mathers Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 22, 2023 · Past) | Director · Since at least Jun 8, 2022 |
| Jay Flatley Other companies: Rivian Automotive, Inc. (Member · Since at least Nov 9, 2021); Denali Therapeutics Inc. (Director · Since at least Dec 7, 2017); Zymergen Inc (Chairman and Acting CEO, Director · Apr 21, 2021 – Oct 19, 2022 · Past); Juno Therapeutics Inc (Director · May 22, 2017 – Mar 5, 2018 · Past); Coherent Corp. (Director · Sep 20, 2011 – Jul 1, 2022 · Past); Illumina, Inc. (Director · Jan 10, 2006 – May 18, 2021 · Past) | Director · May 25, 2021 – May 25, 2021 · Past |
| Mostafa Ronaghi Other companies: Summit Therapeutics Inc. (Non-Executive Director · Since at least Apr 11, 2024); Seer, Inc. (Director · Feb 13, 2021 – Jun 14, 2023 · Past); Illumina, Inc. (SVP, Entrepreneurial Devlopmt · Apr 23, 2013 – Dec 10, 2020 · Past) | Chief Executive Officer, Director · May 25, 2021 – May 25, 2021 · Past |
| Kanya Rajangam Other companies: Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jun 3, 2024 · Past); Nkarta, Inc. (Chief Medical Officer · Jul 9, 2020 – Jan 14, 2022 · Past) | Pres. & Chief Med. & Dev. Off. · Since at least Jul 5, 2022 |
| Brenda Cooperstone Other companies: Lexeo Therapeutics, Inc. (Board Member · Since at least Nov 2, 2023) | Director · Since at least Jun 8, 2022 |
| Deborah Knobelman Other companies: Kronos Bio Inc (President & Interim CEO · Since at least Jun 3, 2024) | Chief Financial Officer · Jun 8, 2022 – Feb 1, 2024 · Past |
| Donald F Tang Other companies: Vicarious Surgical, Inc. (Director · Since at least Jul 14, 2020) | Director · Since at least Dec 9, 2024 |
| Fran Schulz Other companies: Edap Tms SA (Director · Since at least Jan 1, 2026) | Director · Since at least Dec 9, 2024 |
| John Harry Cross III Other companies: Chanticleer Holdings Inc (Chief Financial Officer · Apr 1, 2020 – Dec 11, 2023 · Past) | Chief Financial Officer · Mar 3, 2025 – Mar 7, 2025 · Past |
| Rowan E Chapman Other companies: Natera, Inc. (Director · Since at least Aug 15, 2019) | Chief Business Officer · May 25, 2021 – May 25, 2021 · Past |
All 19 people
| Person | Seat |
|---|---|
| Yvonne Li Other companies: OncoMed Pharmaceuticals Inc (See Remarks · Mar 16, 2018 – Apr 23, 2019 · Past) | Interim CFO · May 4, 2024 – May 4, 2024 · Past |
| Bryan Baum | Director · Since at least Jul 18, 2025 |
| Feng Hsiung | Director · Since at least Mar 7, 2025 |
| Fran Schulz | Director · Since at least Dec 2, 2024 |
| Jay Cross | Chief Financial Officer · Since at least Feb 25, 2025 |
| Jenene Thomas | Chief Executive Officer · Since at least Jan 14, 2026 |
| Philip J Lee | Chief Technology Officer · Jun 8, 2022 – Feb 1, 2023 · Past |
| Susan D Berland | Director · Jun 8, 2022 – Jun 16, 2023 · Past |
| Timothy K Lu | CEO, Director · Since at least Jun 8, 2022 |
Log in to ask 6ix AI your own questions about Senti Biosciences Holdings, Inc.